A Phase 2 study of JCXH-105 vs Shingrix in Herpes Zoster

Study Description

A Study Evaluating a New Herpes Zoster (Shingles) Vaccine Compared to an Approved Vaccine

Study Details

Registry ID:

NCT06581575

Conditions:

Herpes Zoster (HZ), Infectious Diseases, Shingles

Phase:

Phase 2

Target Enrollment:

467 participants

Start Date:

October 16, 2024

Age Range:

50–999 years

Healthy Volunteers:

No

Study Locations (13 sites)

• DM Clinical Research - Boston
  Brookline, MassachusettsUnited States, United States
• DM Clinical Research - New Jersey
  Jersey City, New JerseyUnited States, United States
• Delricht Research
  Charleston, South CarolinaUnited States, United States
• DM Clinical Research - Detroit
  Southfield, MichiganUnited States, United States
• DM Clinical Research - Chicago
  Chicago, IllinoisUnited States, United States
• DM Clinical Research - Sugarland
  Sugarland, TexasUnited States, United States
• DM Clinical Research - Sugarland
  Sugar Land, TexasUnited States, United States
• Delricht Research
  Prosper, TexasUnited States, United States
• Quality Clinical Research
  Omaha, NebraskaUnited States, United States
• Noble Clinical Research
  Tucson, ArizonaUnited States, United States
• Las Vegas Clinical Research
  North Las Vegas, NevadaUnited States, United States
• Long Beach Research Institute
  Long Beach, CaliforniaUnited States, United States
• San Jose Clinical Trials
  San Jose, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →